Tesamorelin for HIV-Associated Lipodystrophy

Candidate profile

Adults living with HIV who have developed lipodystrophy with excess visceral adipose tissue (VAT) — the deep abdominal fat that accumulates around the organs and is associated with metabolic and cardiovascular risk. This is the population studied in the registration trials and reflected on the label. The most appropriate candidates are on stable antiretroviral therapy, have a confirmed diagnosis of central fat accumulation, and are managed by a clinician who can monitor treatment.

Importantly, this is one of the few peptide use cases on this site that describes a genuinely approved indication rather than an off-label or research-only rationale. Tesamorelin (marketed as Egrifta) received FDA approval specifically to reduce excess abdominal visceral fat in HIV-associated lipodystrophy. That distinction matters: the evidence here is regulatory-grade, not extrapolated from rodent studies.

How tesamorelin works

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it stimulates the pituitary to release the body's own growth hormone in a more physiological, pulsatile pattern. The downstream rise in GH and IGF-1 promotes lipolysis, with a pronounced effect on visceral fat depots.

The relevance to HIV-associated lipodystrophy is mechanistic and specific: the syndrome features a blunted GH axis alongside abnormal visceral fat accumulation, so a GHRH analog addresses a plausible upstream driver rather than simply masking a symptom. Reducing VAT is the intended, measured outcome.

What the evidence does and doesn't show

• It does show meaningful reductions in visceral adipose tissue over the treatment period in the pivotal trials — the basis for approval. Improvements in some metabolic and body-image measures were also reported.
• It does not show that tesamorelin cures lipodystrophy or permanently changes fat distribution. The benefit is maintenance-dependent.
• It does not meaningfully reduce subcutaneous fat the way it reduces visceral fat; the effect is depot-specific.
• The effect reverses on discontinuation. When tesamorelin is stopped, visceral fat tends to return toward baseline. This is a treatment, not a one-time correction, which shapes how clinicians and patients think about the commitment.

Realistic expectations

Expect a gradual reduction in visceral fat over months of continued use, assessed by imaging or clinical measures rather than the scale alone — because the change is in a specific compartment, total body weight is not the right yardstick. Response varies between individuals, and continued benefit requires continued treatment. Lifestyle factors (diet, activity, and overall metabolic health) remain part of the picture and are not displaced by the drug.

Patients should also understand that tesamorelin is delivered by daily subcutaneous injection and that adherence matters for sustained effect. It is not a quick or permanent fix.

Safety, monitoring & anti-doping

Because tesamorelin raises IGF-1, monitoring IGF-1 levels is a standard part of therapy — persistently elevated IGF-1 may prompt dose review or discontinuation. Clinicians typically also watch glucose tolerance, since GH-axis stimulation can influence insulin sensitivity, and remain alert to fluid retention, joint symptoms, or injection-site reactions. Tesamorelin is contraindicated in the setting of active malignancy and in pregnancy, and its use is guided by a prescriber who weighs these factors.

For athletes, GHRH analogs and agents that raise growth hormone and IGF-1 fall under the WADA prohibited list at all times. Even though tesamorelin has a legitimate approved medical use, that approval does not exempt a competitive athlete from anti-doping rules; a therapeutic use exemption pathway exists but is a formal, clinician-driven process.

Where this sits

Tesamorelin for HIV-associated lipodystrophy is the unusual case where a peptide's use rests on a formal regulatory approval and controlled-trial evidence for a defined population. That does not make it a general-purpose fat-loss agent or a wellness product — its studied benefit is specific to reducing excess visceral fat in this clinical context, it must be maintained to persist, and it carries monitoring obligations around IGF-1 and metabolic parameters. Understood on those terms, it is a well-characterized, prescriber-managed therapy rather than an experimental one. This overview is educational and is not medical advice or a recommendation to self-treat.